Abstract: The invention relates methods of reducing the risk or preventing the occurrence of an adverse event (AE) or a serious adverse event (SAE) associated with a medical treatment comprising inhalation of nitric oxide.

Abstract: The invention relates methods of reducing the risk or preventing the occurrence of an adverse event (AE) or a serious adverse event (SAE) associated with a medical treatment comprising inhalation of nitric oxide.

Abstract: Disclosed are methods of reducing the risk that a medical treatment comprising inhalation of nitric oxide gas will induce an increase in pulmonary capillary wedge pressure in pediatric patients, leading to pulmonary edema. The methods include avoiding or discontinuing administration of inhaled nitric oxide to a pediatric patient determined to have pre-existing left ventricular dysfunction but who otherwise is a candidate for inhaled nitric oxide treatment (e.g., for pulmonary hypertension), and administering inhaled nitric oxide to pediatric patients who are candidates for such treatment and who are determined not to have pre-existing left ventricular dysfunction.

Abstract: Disclosed are methods of reducing the risk that a medical treatment comprising inhalation of nitric oxide gas will induce an increase in pulmonary capillary wedge pressure in pediatric patients, leading to pulmonary edema. The methods include avoiding or discontinuing administration of inhaled nitric oxide to a pediatric patient determined to have pre-existing left ventricular dysfunction but who otherwise is a candidate for inhaled nitric oxide treatment (e.g., for pulmonary hypertension), and administering inhaled nitric oxide to pediatric patients who are candidates for such treatment and who are determined not to have pre-existing left ventricular dysfunction.

Abstract: Disclosed are methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation. The methods include, for example, obtaining a cylinder containing nitric oxide gas and supplying the cylinder to a medical provider along with instructions regarding how to administer the gas safely to pediatric patients, the instructions including information that patients who have pre-existing left ventricular dysfunction and are administered inhaled nitric oxide may experience pulmonary edema.

Abstract: Disclosed are methods of reducing the risk that a medical treatment comprising inhalation of nitric oxide gas will induce an increase in pulmonary capillary wedge pressure in pediatric patients, leading to pulmonary edema. The methods include avoiding or discontinuing administration of inhaled nitric oxide to a pediatric patient determined to have pre-existing left ventricular dysfunction but who otherwise is a candidate for inhaled nitric oxide treatment (e.g., for pulmonary hypertension), and administering inhaled nitric oxide to pediatric patients who are candidates for such treatment and who are determined not to have pre-existing left ventricular dysfunction.

Abstract: Disclosed are methods of reducing the risk that a medical treatment comprising inhalation of nitric oxide gas will induce an increase in pulmonary capillary wedge pressure in pediatric patients, leading to pulmonary edema. The methods include avoiding or discontinuing administration of inhaled nitric oxide to a pediatric patient determined to have pre-existing left ventricular dysfunction but who otherwise is a candidate for inhaled nitric oxide treatment (e.g., for pulmonary hypertension), and administering inhaled nitric oxide to pediatric patients who are candidates for such treatment and who are determined not to have pre-existing left ventricular dysfunction.

Abstract: Disclosed are methods of distributing a pharmaceutical product comprising nitric oxide gas. The methods include supplying a source of nitric oxide gas to a medical provider, informing the medical provider about a recommended dose of inhaled nitric oxide gas for treatment of neonates with hypoxic respiratory failure, and providing a warning about use of inhaled nitric oxide in patients with pre-existing left ventricular dysfunction.

Abstract: Disclosed are methods of reducing the risk that a medical treatment comprising inhalation of nitric oxide gas will induce an increase in pulmonary capillary wedge pressure in the patient, leading to pulmonary edema.

Abstract: Disclosed are methods of reducing the risk of occurrence of pulmonary edema associated with a medical treatment comprising inhalation of nitric oxide gas.

Abstract: The invention relates methods of reducing the risk or preventing the occurrence of an adverse event (AE) or a serious adverse event (SAE) associated with a medical treatment comprising inhalation of nitric oxide.

Abstract: The invention relates methods of reducing the risk or preventing the occurrence of an adverse event (AE) or a serious adverse event (SAE) associated with a medical treatment comprising inhalation of nitric oxide.

Abstract: The invention relates methods of reducing the risk or preventing the occurrence of an adverse event (AE) or a serious adverse event (SAE) associated with a medical treatment comprising inhalation of nitric oxide.

Abstract: The invention relates methods of reducing the risk or preventing the occurrence of an adverse event (AE) or a serious adverse event (SAE) associated with a medical treatment comprising inhalation of nitric oxide.

Abstract: The invention relates methods of reducing the risk or preventing the occurrence of an adverse event (AE) or a serious adverse event (SAE) associated with a medical treatment comprising inhalation of nitric oxide.

Abstract: The invention relates methods of reducing the risk or preventing the occurrence of an adverse event (AE) or a serious adverse event (SAE) associated with a medical treatment comprising inhalation of nitric oxide.